Take Control of Your Health with New Technologies

In the last few years, we’ve seen an explosion in consumer health devices, from watches that monitor your heart rate to apps that track everything from sleep to blood pressure to calories. Wearable devices put people’s health information directly in their own hands whenever they need it, and telemedicine helps patients and physicians get connected with the click of a button. These and other healthcare tools are empowering patients to take an active role in their health and are bridging the information gap between patients and physicians.

However, various misconceptions, anxieties and fears still keep patients from talking openly with their doctors, particularly when it comes to heart disease.

Major Medical Anxieties

HeartFlow’s recent consumer survey of 1,500 Americans found that despite 42 percent of Americans knowing that they have a family history of heart disease and another 77 percent admitting to worrying about their heart health, most (67 percent) have never sought diagnosis or treatment. Specific to cardiac care, the most common fear (30 percent) is misdiagnosis or a completely missed diagnosis. What’s more, 79 percent of respondents would prefer having a root canal or fender bender over undergoing unnecessary hospital tests.
Fortunately, new technologies can encourage better communication between physicians and their patients, and many patients are now enabled to more actively manage their heart health. These new tools also encourage patients to live healthier lifestyles. By tracking activity and providing real-time insights, wearables and health apps encourage regular exercise and healthy eating, which can help cut down the risk of heart disease.

How Technology Can Help

Meanwhile, a better understanding of the advances in heart health technologies available could help to alleviate patient fears. For example, artificial intelligence (AI) and deep learning are driving innovation in non-invasive testing modalities and remote monitoring tools. AI can help physicians make informed diagnoses and treatment decisions, while remote monitoring and telemedicine allow physicians to review patient data and perform virtual consultations without requiring an office visit.

Some people are eager to adopt new technologies in their everyday lives, but does that mean that they’re willing to embrace new technology when it comes to their healthcare? HeartFlow’s survey suggests that consumers are becoming more comfortable with new technologies, with 78 percent of respondents indicating they trust artificial intelligence technology, for example, to assist doctors with their tasks. Additionally, 78 percent think a combination of technology and human analysis results in the most accurate diagnosis, over either alone.

We’re excited by a future of precision medicine in which healthcare combines the power of both physician expertise and advanced technology to provide optimal, tailored care for each patient, every time. Each technological advance and meaningful physician-patient interaction gets us one step closer; we hope we are doing our part.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.